This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choi, H. Articles by Benjamin, R. S. Search for Related Content PubMed PubMed Citation Articles by Choi, H. Articles by Benjamin, R. S. Social Bookmarking                            What's this?

Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

Haesun Choi, Chuslip Charnsangavej, Silvana C. Faria, Homer A. Macapinlac, Michael A. Burgess, Shreyaskumar R. Patel, Lei L. Chen, Donald A. Podoloff, Robert S. Benjamin

From the Division of Diagnostic Imaging and Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Radiology, University of San Diego, San Diego, CA; and Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Address reprint requests to Haesun Choi, MD, Division of Diagnostic Imaging, Box 368, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: hchoi{at}mdanderson.org

Purpose Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors (GISTs) treated with imatinib. This study evaluates whether computed tomography (CT) findings of GIST after imatinib treatment correlate with tumor responses by [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) and develops reliable, quantitative, CT response criteria.

Patients and Methods A total of 172 lesions selected by RECIST were evaluated in 40 patients with metastatic GISTs treated with imatinib. All patients had pretreatment and 2-month follow-up CTs and FDG-PETs. Multivariate analysis was performed using tumor size and density (Hounsfield unit [HU]) on CT and maximum standardized uptake value (SUV_max) on FDG-PET. Patients were observed up to 28 months.

Results Mean baseline tumor size and density on CT were 5.3 cm and 72.8 HU, respectively, and mean baseline SUV_max on FDG-PET was 5.8. Thirty-three patients had good response on FDG-PET. A decrease in tumor size of more than 10% or a decrease in tumor density of more than 15% on CT had a sensitivity of 97% and a specificity of 100% in identifying PET responders versus 52% and 100% by RECIST. Good responders on CT at 2 months had significantly longer time to progression than those who did not respond (P = .01).

Conclusion Small changes in tumor size or density on CT are sensitive and specific methods of assessing the response of GISTs. If the prognostic value of our proposed CT response criteria can be confirmed prospectively, the criteria should be employed in future studies of patients with GIST.

Supported by NCI Contracts No. U01-CA70172-01 and N01-CM-17003.

Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL; presented in part at the 9th Annual Meeting of the Connective Tissue Oncology Society, November 11-13, 2004, Montreal, Quebec, Canada.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. P. Singh, D. Yang, M. Ravoori, L. Han, and V. Kundra In Vivo Functional and Anatomic Imaging for Assessment of in Vivo Gene Transfer Radiology, July 8, 2009; (2009) 2531081825. [Abstract] [Full Text]

				S. George, P. Merriam, R. G. Maki, A. D. Van den Abbeele, J. T. Yap, T. Akhurst, D. C. Harmon, G. Bhuchar, M. M. O'Mara, D. R. D'Adamo, et al. Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas J. Clin. Oncol., July 1, 2009; 27(19): 3154 - 3160. [Abstract] [Full Text] [PDF]

				S. Stacchiotti, A. Marrari, E. Tamborini, E. Palassini, E. Virdis, A. Messina, F. Crippa, C. Morosi, A. Gronchi, S. Pilotti, et al. Response to imatinib plus sirolimus in advanced chordoma Ann. Onc., July 1, 2009; (2009) mdp210v1. [Abstract] [Full Text] [PDF]

				K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				S. Stacchiotti, P. Collini, A. Messina, C. Morosi, M. Barisella, R. Bertulli, C. Piovesan, P. Dileo, V. Torri, A. Gronchi, et al. High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment--Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria Radiology, May 1, 2009; 251(2): 447 - 456. [Abstract] [Full Text] [PDF]

				T. W. Kim, M.-H. Ryu, H. Lee, S. J. Sym, J.-L. Lee, H. M. Chang, Y. S. Park, K. H. Lee, W. K. Kang, D. B. Shin, et al. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Oncologist, May 1, 2009; 14(5): 540 - 547. [Abstract] [Full Text] [PDF]

				L. K. Shankar, A. Van den Abbeele, J. Yap, R. Benjamin, S. Scheutze, and T.J. FitzGerald Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology Clin. Cancer Res., March 15, 2009; 15(6): 1891 - 1897. [Abstract] [Full Text] [PDF]

				N. Dhani, D. Tu, D. J. Sargent, L. Seymour, and M. J. Moore Alternate Endpoints for Screening Phase II Studies Clin. Cancer Res., March 15, 2009; 15(6): 1873 - 1882. [Abstract] [Full Text] [PDF]

				B. Zhao, L. H. Schwartz, and S. M. Larson Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers J. Nucl. Med., February 1, 2009; 50(2): 239 - 249. [Abstract] [Full Text] [PDF]

				S. J. Crabb, D. Patsios, E. Sauerbrei, P. M. Ellis, A. Arnold, G. Goss, N. B. Leighl, F. A. Shepherd, J. Powers, L. Seymour, et al. Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer J. Clin. Oncol., January 20, 2009; 27(3): 404 - 410. [Abstract] [Full Text] [PDF]

				J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]

				M. R. Benz, M. S. Allen-Auerbach, F. C. Eilber, H. J.J. Chen, S. Dry, M. E. Phelps, J. Czernin, and W. A. Weber Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas J. Nucl. Med., October 1, 2008; 49(10): 1579 - 1584. [Abstract] [Full Text] [PDF]

				I. E. Haines Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective J. Clin. Oncol., July 20, 2008; 26(21): 3650 - 3652. [Full Text] [PDF]

				S. Sleijfer and E. Wiemer In Reply J. Clin. Oncol., July 20, 2008; 26(21): 3652 - 3653. [Full Text] [PDF]

				C. Mussi, H.-U. Schildhaus, A. Gronchi, E. Wardelmann, and P. Hohenberger Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 Clin. Cancer Res., July 15, 2008; 14(14): 4550 - 4555. [Abstract] [Full Text] [PDF]

				A. A.M. van der Veldt, M. R. Meijerink, A. J.M. van den Eertwegh, A. Bex, G. de Gast, J. B.A.G. Haanen, and E. Boven Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response Clin. Cancer Res., April 15, 2008; 14(8): 2431 - 2436. [Abstract] [Full Text] [PDF]

				H. Choi Response Evaluation of Gastrointestinal Stromal Tumors Oncologist, April 1, 2008; 13(suppl_2): 4 - 7. [Abstract] [Full Text] [PDF]

				S. M. Schuetze, L. H. Baker, R. S. Benjamin, and R. Canetta Selection of Response Criteria for Clinical Trials of Sarcoma Treatment Oncologist, April 1, 2008; 13(suppl_2): 32 - 40. [Abstract] [Full Text] [PDF]

				A. Hajitou, D. C. Lev, J. A. F. Hannay, B. Korchin, F. I. Staquicini, S. Soghomonyan, M. M. Alauddin, R. S. Benjamin, R. E. Pollock, J. G. Gelovani, et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging PNAS, March 18, 2008; 105(11): 4471 - 4476. [Abstract] [Full Text] [PDF]

				C. H. Holdsworth, R. D. Badawi, J. B. Manola, M. F. Kijewski, D. A. Israel, G. D. Demetri, and A. D. Van den Abbeele CT and PET: Early Prognostic Indicators of Response to Imatinib Mesylate in Patients with Gastrointestinal Stromal Tumor Am. J. Roentgenol., December 1, 2007; 189(6): W324 - W330. [Abstract] [Full Text] [PDF]